-
Founded in:
2001-01-17 -
Country:
China -
Address:
Yancheng Xiangshui County Economic Development Zone -
Tax NO.:
91320921703859698E -
Registered Funds:
40 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Metronidazole |
Extract from the above information
More
Extract from the above information |
443-48-1 | 39 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Clonidine hydrochloride |
Clonidine is an alpha receptor agonist. Clonidine directly stimulates the alpha 2 receptors on the central postsynaptic membrane of the hypothalamus and medulla oblongata, excites inhibitory neurons, reduces the outflow of central sympathetic nerve impulses, and thus inhibits peripheral sympathetic nerve activity. Clonidine also stimulates the alpha 2 receptors on the presynaptic membrane of peripheral sympathetic nerves, enhancing their negative feedback, reducing the release of norepinephrine from peripheral nerve terminals, reducing peripheral vascular and renal vascular resistance, slowing heart rate, and lowering blood pressure. Renal blood flow and glomerular filtration rate remain essentially unchanged. Orthostatic symptoms are mild or less common, and postural hypotension rarely occurs. Clonidine hydrochloride causes a moderate decrease (15%~20%) in supine cardiac output without changing peripheral vascular resistance; a slight decrease in 45° tilt
More
Clonidine is an alpha receptor agonist. Clonidine directly stimulates the alpha 2 receptors on the central postsynaptic membrane of the hypothalamus and medulla oblongata, excites inhibitory neurons, reduces the outflow of central sympathetic nerve impulses, and thus inhibits peripheral sympathetic nerve activity. Clonidine also stimulates the alpha 2 receptors on the presynaptic membrane of peripheral sympathetic nerves, enhancing their negative feedback, reducing the release of norepinephrine from peripheral nerve terminals, reducing peripheral vascular and renal vascular resistance, slowing heart rate, and lowering blood pressure. Renal blood flow and glomerular filtration rate remain essentially unchanged. Orthostatic symptoms are mild or less common, and postural hypotension rarely occurs. Clonidine hydrochloride causes a moderate decrease (15%~20%) in supine cardiac output without changing peripheral vascular resistance; a slight decrease in 45° tilt |
4205-91-8 | 23 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sildenafil citrate |
Extract from the above information
More
Extract from the above information |
171599-83-0 | 66 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sildenafil citrate |
This product is an oral drug for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting phosphodiesterase type 5 (PDE5) that breaks down cGMP in the corpus cavernosum, it increases the level of cGMP in the corpus cavernosum, relaxes smooth muscles, and allows blood to flow into the corpus cavernosum, exerting its effect during sexual stimulation.
More
This product is an oral drug for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting phosphodiesterase type 5 (PDE5) that breaks down cGMP in the corpus cavernosum, it increases the level of cGMP in the corpus cavernosum, relaxes smooth muscles, and allows blood to flow into the corpus cavernosum, exerting its effect during sexual stimulation. |
171599-83-0 | 66 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sildenafil citrate |
This product is an oral medication for the treatment of erectile dysfunction. It is the citrate of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5) that breaks down cGMP in the corpus cavernosum, increases the level of cGMP in the corpus cavernosum during sexual stimulation, relaxes smooth muscles, and blood flows into the corpus cavernosum. In the absence of sexual stimulation, the recommended dose of sildenafil has no effect.
More
This product is an oral medication for the treatment of erectile dysfunction. It is the citrate of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5) that breaks down cGMP in the corpus cavernosum, increases the level of cGMP in the corpus cavernosum during sexual stimulation, relaxes smooth muscles, and blood flows into the corpus cavernosum. In the absence of sexual stimulation, the recommended dose of sildenafil has no effect. |
171599-83-0 | 66 |